+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligo (Primer), Reagents), Type (Custom, Predesigned), Application (Therapeutic (ASO, siRNA), Research (PCR, Sequencing, Diagnostics)), End-user (Pharma, CROS, CMOs), and Region - Forecast to 2027

  • PDF Icon

    Report

  • 297 Pages
  • November 2022
  • Region: Global
  • Markets and Markets
  • ID: 5312415

Increasing Use of Synthesized Oligos in Therapeutic Applications

The global oligonucleotide synthesis market is projected to reach USD 16.7 billion by 2027 from USD 7.7 billion in 2022, at a CAGR of 16.8% during the forecast period. Market growth can be attributed to the increasing ongoing clinical trials for oligonucleotide-based therapies for leading therapeutic areas such as oncology.

The primers segment will grow at the highest rate in the synthesized oligos market, by product

By product, the synthesized oligonucleotides market segment is divided into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos. Primers are expected to show the highest growth over the forecast period owing to their wide applications in PCR, sequencing, gene synthesis, and cloning.

By therapeutic application, the antisense oligonucleotide-based therapies segment accounted for the largest share of the oligonucleotide synthesis market in 2021

The therapeutic application segment is further segmented into antisense oligonucleotide-based therapies, siRNA oligonucleotide-based therapies, and CpG oligonucleotide-based therapies. In 2021, antisense oligos accounted for the largest share of this segment as they form the basis of many therapies that are currently in clinical trials, thus boosting segment growth.

Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Germany), Kaneka Corporation (Japan), Biolegio B.V. (Netherlands), Biolytic Lab Performance Inc. (US), Microsynth AG (Switzerland), ATDBio Ltd. (UK), Twist Bioscience Corporation (US), Eton Bioscience, Inc. (US), CSBIO (US), Tag Copenhagen A/S (Denmark), Biogen Inc. (US), Sarepta Therapeutics, Inc. (US), Ionis Pharmaceuticals, Inc. (US), and Alnylam Pharmaceuticals, Inc. (US) are some of the major players operating in the market.

Asia-Pacific region will register a highest CAGR in the oligonucleotide synthesis market

The market for oligonucleotide synthesis in Asia-Pacific is anticipated to develop at the fastest rate during the forecast period. Growing R&D funding and research activity, increased product availability and decreased outsourcing costs are some of the factors that are likely to propel market growth.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side - 80% and Demand Side - 20%
  • By Designation: Managers - 45%, CXOs, Director level - 30%, and Executives - 25%
  • By Region: North America - 20%, Europe - 10%, Asia-Pacific - 55%, and RoW - 15%

List of Companies Profiled in the Report

  • Thermo Fisher Scientific, Inc. (US)
  • Merck KGaA (Germany)
  • Danaher Corporation (US)
  • LGC Limited (UK)
  • Maravai Life Sciences (US)
  • Agilent Technologies, Inc. (US)
  • Eurofins Scientific (Germany)
  • Kaneka Corporation (Japan)
  • Biolegio B.V. (Netherlands)
  • Biolytic Lab Performance Inc. (US)
  • Microsynth AG (Switzerland)
  • ATDBio Ltd. (UK)
  • Twist Bioscience Corporation (US)
  • Eton Bioscience, Inc. (US)
  • CSBIO (US)
  • Tag Copenhagen A/S (Denmark)
  • Generi Biotech (Czech Republic)
  • Biocomma Limited (China)
  • Hongene Biotech Corporation (China)
  • Hangzhou Pharm & Chem Co. Ltd (China)
  • Tokyo Chemical Industry Co. Ltd. (Japan)
  • Biogen Inc. (US)
  • Sarepta Therapeutics, Inc. (US)
  • Ionis Pharmaceuticals, Inc. (US)
  • Alnylam Pharmaceuticals, Inc. (US)

Research Coverage

This report provides a detailed picture of the oligonucleotide synthesis market. It aims to estimate the market’s size and future growth potential across different segments such as the product, application, end-user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

Table of Contents

1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Inclusions & Exclusions
1.3.3 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
1.7 Summary of Changes

2 Research Methodology
2.1 Research Data
2.1.1 Secondary Sources
2.1.1.1 Key Data from Secondary Sources
2.1.2 Primary Sources
2.1.2.1 Key Data from Primary Sources
2.2 Market Size Estimation
2.1.1 Revenue Share Analysis
2.1.2 Illustrative Figure of Revenue Share Analysis
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation
2.5 Assumptions for the Study

3 Executive Summary4 Premium Insights
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.2 Restraints
5.2.3 Opportunities
5.2.4 Challenges
5.3 Market Trends
5.4 Ranges/Scenario
5.5 Trends/Disruptions Impacting Customer's Business/YC-YCC Shift
5.6 Indicative Pricing Model Analysis
5.7 Value Chain Analysis
5.8 Supply Chain Analysis
5.9 Ecosystem Analysis
5.10 Technology Analysis
5.11 Patent Analysis
5.12 Key Conferences & Events in 2022-23
5.13 Regulatory Landscape
5.14 Regulatory Bodies, Government Agencies and Other Organizations
5.15 Porter's Five Forces Analysis
5.16 Key Stakeholders and Buying Criteria

6 Oligonucleotide Synthesis Market, by Product
6.1 Introduction
6.2 Oligonucleotide-based Drugs
6.3 Synthesized Oligonucleotides
6.3.1 By Product
6.3.1.1 Primers
6.3.1.2 Probes
6.3.1.3 DNA Oligos
6.3.1.4 RNA Oligos
6.3.1.5 Other Synthesized Oligos [Bridged Nucleic Acid (BNA), Locked Nucleic Acid (LNA)]
6.3.2 By Type
6.3.2.1 Custom Oligonucleotides
6.3.2.2 Predesigned Oligos
6.4 Reagents
6.5 Equipment

7 Oligonucleotide Synthesis Market, by Application
7.1 Introduction
7.2 Therapeutic Applications
7.2.1 By Type
7.2.1.1 Antisense Oligonucleotide-based Therapies
7.2.1.2 siRNA Oligonucleotide-based Therapies
7.2.1.3 CPG Oligonucleotide-based Therapies
7.2.2 By Disease Type
7.2.1.1 Neurological Disorders
7.2.1.2 Infectious Diseases
7.2.1.3 Other Diseases (Rare Genetic Diseases, Cardiovascular Diseases, Cancer, Inflammatory Diseases, Autoimmune Disease)
7.3 Diagnostic Applications
7.4 Research Applications
7.4.1 PCR
7.4.2 Sequencing
7.4.3 Other Research Applications (Nucleic Acid Hybridization Methods, Microarrays, Southern Blotting Methods)

8 Oligonucleotide Synthesis Market, by End-user
8.1 Introduction
8.2 Hospitals
8.3 Pharmaceutical & Biotechnology Companies
8.4 Diagnostic Laboratories
8.5 CROs & CMOs
8.6 Academic Research Institutes

9 Oligonucleotide Synthesis Market, by Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 UK
9.3.4 Italy
9.3.5 Spain
9.3.6 RoE
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.6 RoAPAC
9.5.1 Latin America
9.5.2 Brazil
9.5.3 Mexico
9.5.4 RoLATAM
9.6 Middle East Africa

10 Competitive Landscape
10.1 Introduction
10.2 Key Player Strategies/Right to Win
10.3 Revenue Analysis
10.4 Market Share Analysis
10.5 Company Evaluation Quadrant
10.5.1 Stars
10.5.2 Emerging Leaders
10.5.3 Pervasive Players
10.5.4 Emerging Companies
10.5.5 Participants
10.6 Company Evaluation Quadrant: Start-Ups/SMEs
16.7 Competitive Benchmarking
16.7.1 Detailed List of Key Startup/SMEs
16.7.2 Competitive Benchmarking of Key Players [Startups/SMEs]
10.7 Competitive Scenario and Trends

11 Company Profiles
11.1 Key Market Players
11.1.1 Danaher Corporation (US)
11.1.2 Thermo Fisher Scientific Inc. (US)
11.1.3 Merck KGaA (Germany)
11.1.4 LGC Limited (UK)
11.1.5 Maravai Life Sciences (US)
11.1.6 Agilent Technologies, Inc. (US)
11.1.7 Eurofins Scientific (Germany)
11.1.8 Kaneka Corporation (Japan)
11.1.9 Biolegio B.V (Netherlands)
11.1.10 Biolytic Lab Performance Inc. (US)
11.1.11 Microsynth AG (Switzerland)
11.1.11.1 Other Players
11.1.12 ATDBio Ltd. (UK)
11.1.13 Twist Bioscience Corporation (US)
11.1.14 Eton Bioscience, Inc. (US)
11.1.15 CSBIO (US)
11.1.16 Tag Copenhagen A/S (Denmark)
11.1.17 Generi Biotech (Czech Republic)
11.1.18 Biocomma Limited (China)
11.1.19 Hongene Biotech Corporation (China)
11.1.20 Hangzhou Pharm & Chem Co. Ltd (China)
11.1.21 Tokyo Chemical Industry Co. Ltd. (Japan)
11.1.21.1 Therapeutic Market Players
11.2.1 Biogen Inc. (US)
11.2.2 Sarepta Therapeutics, Inc. (US)
11.2.3 Ionis Pharmaceuticals, Inc. (US)
11.2.4 Alnylam Pharmaceuticals, Inc. (US)

12 Appendix
12.1 Discussion Guide
12.2 Knowledge Store: The Subscription Portal
12.3 Available Customisations

Executive Summary

Companies Mentioned

  • Agilent Technologies, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • ATDBio Ltd.
  • Biocomma Limited
  • Biogen Inc.
  • Biolegio B.V
  • Biolytic Lab Performance Inc.
  • CSBIO
  • Danaher Corporation
  • Eton Bioscience, Inc.
  • Eurofins Scientific
  • Generi Biotech
  • Hangzhou Pharm & Chem Co. Ltd
  • Hongene Biotech Corporation
  • Ionis Pharmaceuticals, Inc.
  • Kaneka Corporation
  • LGC Limited
  • Maravai Life Sciences
  • Merck KGaA
  • Microsynth AG
  • Sarepta Therapeutics, Inc.
  • Tag Copenhagen A/S
  • Thermo Fisher Scientific Inc.
  • Tokyo Chemical Industry Co. Ltd.
  • Twist Bioscience Corporation

Methodology

Loading
LOADING...

Table Information